Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 26, 2001

View Archived Issues

Flamel Technologies completes controlled-release antibiotic study

Amgen submits supplemental application with EMEA for anemia product

Genzyme General highlights Q3 developments

Catalytic antioxidant AEOL-10150 protects hamsters against radiation-induced mucositis

Combination of CCI-779 and 5-FU/LV associated with significant toxicity in phase I study

European Generx trial approved and set to commence

Impact of addition of BMS-275291 to paclitaxel/carboplatin examined in phase II/III trial in NSCLC

Merck KGaA and Forest to comarket treatment for alcohol addiction in the U.S.

Antimicrotubule agent T-900607 well tolerated in ongoing phase I trial in advanced cancer patients

Novel platinum analogue shows evidence of activity, adequate safety in phase II cancer trials

Tissue engineering product to begin clinical trials in the U.S.

SU-5416 may be useful in certain patients with c-kit-positive AML, according to phase II data

Gilead licenses its SELEX technology to Archemix

NXY-059 may have advantages over current neuroprotectants for the treatment of stroke

Merger of Barr and Duramed finalized this week

Oxigene regains rights to anticancer combretastatins, ends development of declopramide

Novartis receives approvable letter for Diovan as treatment for heart failure

ACG news: pilot study of APC-2059 demonstrates safety and activity in ulcerative colitis

Second activated macrophage therapy trial initiated in Belgium

Novel protein identified at CuraGen shows promise in IBD

Pyrimidines inhibit CDKs and FAK according to recent AstraZeneca patent

New series synthesized at Bayer shows inhibitory activity against cGMP-PDE

Takeda discloses agents for inflammation, arthritis and bone disorders

Scios patents discoveries in the field of bradykinin antagonists

New chroman derivatives designed at Akzo Nobel with affinity for estrogen receptors

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...